Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

Joe Y. Chang, Salma K. Jabbour, Dirk De Ruysscher, Steven E. Schild, Charles B. Simone, Ramesh Rengan, Steven Feigenberg, Atif J. Khan, Noah C. Choi, Jeffrey D. Bradley, Xiaorong R. Zhu, Antony J. Lomax, Bradford S. Hoppe

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Radiation dose escalation has been shown to improve local control and survival in patients with non-small cell lung cancer in some studies, but randomized data have not supported this premise, possibly owing to adverse effects. Because of the physical characteristics of the Bragg peak, proton therapy (PT) delivers minimal exit dose distal to the target volume, resulting in better sparing of normal tissues in comparison to photon-based radiation therapy. This is particularly important for lung cancer given the proximity of the lung, heart, esophagus, major airways, large blood vessels, and spinal cord. However, PT is associated with more uncertainty because of the finite range of the proton beam and motion for thoracic cancers. PT is more costly than traditional photon therapy but may reduce side effects and toxicity-related hospitalization, which has its own associated cost. The cost of PT is decreasing over time because of reduced prices for the building, machine, maintenance, and overhead, as well as newer, shorter treatment programs. PT is improving rapidly as more research is performed particularly with the implementation of 4-dimensional computed tomography-based motion management and intensity modulated PT. Given these controversies, there is much debate in the oncology community about which patients with lung cancer benefit significantly from PT. The Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee task group intends to address the issues of PT indications, advantages and limitations, cost-effectiveness, technology improvement, clinical trials, and future research directions. This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions.

Original languageEnglish (US)
Pages (from-to)505-516
Number of pages12
JournalInternational Journal of Radiation Oncology Biology Physics
Volume95
Issue number1
DOIs
StatePublished - May 1 2016

Fingerprint

Proton Therapy
Non-Small Cell Lung Carcinoma
lungs
therapy
cancer
protons
Photons
Lung Neoplasms
Thorax
indication
Costs and Cost Analysis
Translational Medical Research
costs
esophagus
dosage
spinal cord
Insurance
cost effectiveness
blood vessels
Esophagus

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. / Chang, Joe Y.; Jabbour, Salma K.; De Ruysscher, Dirk; Schild, Steven E.; Simone, Charles B.; Rengan, Ramesh; Feigenberg, Steven; Khan, Atif J.; Choi, Noah C.; Bradley, Jeffrey D.; Zhu, Xiaorong R.; Lomax, Antony J.; Hoppe, Bradford S.

In: International Journal of Radiation Oncology Biology Physics, Vol. 95, No. 1, 01.05.2016, p. 505-516.

Research output: Contribution to journalArticle

Chang, JY, Jabbour, SK, De Ruysscher, D, Schild, SE, Simone, CB, Rengan, R, Feigenberg, S, Khan, AJ, Choi, NC, Bradley, JD, Zhu, XR, Lomax, AJ & Hoppe, BS 2016, 'Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer', International Journal of Radiation Oncology Biology Physics, vol. 95, no. 1, pp. 505-516. https://doi.org/10.1016/j.ijrobp.2016.01.036
Chang, Joe Y. ; Jabbour, Salma K. ; De Ruysscher, Dirk ; Schild, Steven E. ; Simone, Charles B. ; Rengan, Ramesh ; Feigenberg, Steven ; Khan, Atif J. ; Choi, Noah C. ; Bradley, Jeffrey D. ; Zhu, Xiaorong R. ; Lomax, Antony J. ; Hoppe, Bradford S. / Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. In: International Journal of Radiation Oncology Biology Physics. 2016 ; Vol. 95, No. 1. pp. 505-516.
@article{d2833e11f49c46c5b05c6c203e04cd0e,
title = "Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer",
abstract = "Radiation dose escalation has been shown to improve local control and survival in patients with non-small cell lung cancer in some studies, but randomized data have not supported this premise, possibly owing to adverse effects. Because of the physical characteristics of the Bragg peak, proton therapy (PT) delivers minimal exit dose distal to the target volume, resulting in better sparing of normal tissues in comparison to photon-based radiation therapy. This is particularly important for lung cancer given the proximity of the lung, heart, esophagus, major airways, large blood vessels, and spinal cord. However, PT is associated with more uncertainty because of the finite range of the proton beam and motion for thoracic cancers. PT is more costly than traditional photon therapy but may reduce side effects and toxicity-related hospitalization, which has its own associated cost. The cost of PT is decreasing over time because of reduced prices for the building, machine, maintenance, and overhead, as well as newer, shorter treatment programs. PT is improving rapidly as more research is performed particularly with the implementation of 4-dimensional computed tomography-based motion management and intensity modulated PT. Given these controversies, there is much debate in the oncology community about which patients with lung cancer benefit significantly from PT. The Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee task group intends to address the issues of PT indications, advantages and limitations, cost-effectiveness, technology improvement, clinical trials, and future research directions. This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions.",
author = "Chang, {Joe Y.} and Jabbour, {Salma K.} and {De Ruysscher}, Dirk and Schild, {Steven E.} and Simone, {Charles B.} and Ramesh Rengan and Steven Feigenberg and Khan, {Atif J.} and Choi, {Noah C.} and Bradley, {Jeffrey D.} and Zhu, {Xiaorong R.} and Lomax, {Antony J.} and Hoppe, {Bradford S.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2016.01.036",
language = "English (US)",
volume = "95",
pages = "505--516",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

AU - Chang, Joe Y.

AU - Jabbour, Salma K.

AU - De Ruysscher, Dirk

AU - Schild, Steven E.

AU - Simone, Charles B.

AU - Rengan, Ramesh

AU - Feigenberg, Steven

AU - Khan, Atif J.

AU - Choi, Noah C.

AU - Bradley, Jeffrey D.

AU - Zhu, Xiaorong R.

AU - Lomax, Antony J.

AU - Hoppe, Bradford S.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Radiation dose escalation has been shown to improve local control and survival in patients with non-small cell lung cancer in some studies, but randomized data have not supported this premise, possibly owing to adverse effects. Because of the physical characteristics of the Bragg peak, proton therapy (PT) delivers minimal exit dose distal to the target volume, resulting in better sparing of normal tissues in comparison to photon-based radiation therapy. This is particularly important for lung cancer given the proximity of the lung, heart, esophagus, major airways, large blood vessels, and spinal cord. However, PT is associated with more uncertainty because of the finite range of the proton beam and motion for thoracic cancers. PT is more costly than traditional photon therapy but may reduce side effects and toxicity-related hospitalization, which has its own associated cost. The cost of PT is decreasing over time because of reduced prices for the building, machine, maintenance, and overhead, as well as newer, shorter treatment programs. PT is improving rapidly as more research is performed particularly with the implementation of 4-dimensional computed tomography-based motion management and intensity modulated PT. Given these controversies, there is much debate in the oncology community about which patients with lung cancer benefit significantly from PT. The Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee task group intends to address the issues of PT indications, advantages and limitations, cost-effectiveness, technology improvement, clinical trials, and future research directions. This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions.

AB - Radiation dose escalation has been shown to improve local control and survival in patients with non-small cell lung cancer in some studies, but randomized data have not supported this premise, possibly owing to adverse effects. Because of the physical characteristics of the Bragg peak, proton therapy (PT) delivers minimal exit dose distal to the target volume, resulting in better sparing of normal tissues in comparison to photon-based radiation therapy. This is particularly important for lung cancer given the proximity of the lung, heart, esophagus, major airways, large blood vessels, and spinal cord. However, PT is associated with more uncertainty because of the finite range of the proton beam and motion for thoracic cancers. PT is more costly than traditional photon therapy but may reduce side effects and toxicity-related hospitalization, which has its own associated cost. The cost of PT is decreasing over time because of reduced prices for the building, machine, maintenance, and overhead, as well as newer, shorter treatment programs. PT is improving rapidly as more research is performed particularly with the implementation of 4-dimensional computed tomography-based motion management and intensity modulated PT. Given these controversies, there is much debate in the oncology community about which patients with lung cancer benefit significantly from PT. The Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee task group intends to address the issues of PT indications, advantages and limitations, cost-effectiveness, technology improvement, clinical trials, and future research directions. This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions.

UR - http://www.scopus.com/inward/record.url?scp=84963596225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963596225&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2016.01.036

DO - 10.1016/j.ijrobp.2016.01.036

M3 - Article

VL - 95

SP - 505

EP - 516

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -